Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2647 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-03-08 (morningstar.se)
5 shares with the largest reductions of estimated fair value after the Q4 result
Stmicroelectronics and Biogen are among the shares that have the largest reductions.
Read more
2025-02-10 (livemint.com)
Biogen Pharmachem Industries Q4 Results 2025 - Find Biogen Pharmachem Industries Q4 Earnings Result | Biogen Pharmachem Industries Q4 results
Biogen Pharmachem Industries Q4 Results: Check out Biogen Pharmachem Industries Q4 Result news, Biogen Pharmachem Industries Q4 Earnings result updates and highlights. | Biogen Pharmachem Industries Q4 Results 2025
Read more
2025-01-29 (nikkeibp.co.jp)
Accepted a high -dosage lamen application for Nuninaracen, which is a SMA therapeutic drug for FDA and EMA:
Kenburi, Masato, USA: January 23, 2025: Biogen Inc. ) Accepted an approval application (SNDA) submitted by Baishin for the high dosage of Nunsenrsen, which is a therapeutic drug, and from the European Commission (EMA). As a result of verification of the application, it has been revealed that it has been accepted. The high -dose administration of the nutsenrsen (spin laza 🄬) is a better initial administration compared to the approved nuinsurusen administration lenvage. It is composed of a lenimin (50 mg is administered twice at 14 days) and a high -dose maintenance lame (28 mg administration for 4 months). Presless resources are Kochira
Read more
2024-12-13 (harvard.edu)
Climate Resilience for Frontline Clinics Toolkit | Climate Resilience for Frontline Clinics and the Patients They Serve | T.H. Chan School of Public Health
The Climate Resilience for Frontline Clinics toolkit, developed in collaboration with Americares, helps protect people on the front lines of climate change.
Read more
2024-11-27 (chemistryworld.com)
Europe reconsiders Alzheimer’s antibody approval
Leqembi recommended for approval with restrictions to reduce side effect risk
Read more
2024-10-27 (manilatimes.net)
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab
Read more
2024-10-20 (163.com)
Cai Lei’s team: The new drug has no effect on Cai Lei and is not suitable for Cai Lei and most types of ALS
Recently, the official website of the State Food and Drug Administration announced that Tofersen injection, a drug produced by Biogen, has been approved for marketing in China. The drug is specifically used to treat adult amyotrophic lateral sclerosis with SOD1 gene mutations. (ALS), ALS. As the world's first anti-ALS treatment drug, Tofsen has attracted widespread attention.
Read more
2024-10-02 (medicalbrief.co.za)
Lupus drug meets main goal of late-stage trial
An experimental lupus treatment has met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.
Read more
2024-09-25 (elpais.com)
Lights and shadows of lecanemab: what is happening with the only drug against Alzheimer's?
Lecanemab, the first drug that has been shown to have an effect against Alzheimer's, is dividing the scientific community.
Read more